Abstract
Frailty is one of the key features of aging and it is associated with a loss of function, an increased risk of falls, and ultimately loss of the ability to live independently. Based on the demographic shift of the older population, as a result of the aging of the baby boomers, interventions to slow or delay the development of frailty will be of increasing importance. One of the physiologic correlates of frailty is the cachexia of aging. The underlying mechanism of the cachexia of aging is cytokine-associated wasting of protein and energy stores and ghrelin receptor agonists target some of these mechanisms. Clinical trials have shown that ghrelin receptor agonists have orexigenic effects, enhance GH secretion, and increase lean body mass and limb fat mass in the elderly. The potential benefits of ghrelin receptor agonists in the treatment of cachexia of aging and of cachexia secondary to various diseases are reviewed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Butler RN. Population aging and health. BMJ. 1997;315:1082–4.
CDC. Public health and aging:trends in aging-United States and worldwide. JAMA. 2003; 289:1371–73.
Michel JP, Newton JL, Kirkwood TB. Medical challenges of improving the quality of a longer life. JAMA. 2008;299:688–90.
Ory MG, Cox DM. Forging ahead: linking health and behavior to improve quality of life in older people. Soc Indic Res. 1994;33:89–120.
Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporosis Int. 1997;7:407–13.
Tinetti ME. Prevention of falls and fall injuries in elderly persons: a research agenda. Prev Med. 1994;23:756–62.
Leveille SG, Guralnik JM, Ferrucci L, Langlois JA. Aging successfully until death in old age: opportunities for increasing active life expectancy. Am J Epidemiol. 1999;149:654–64.
Fried LP, Guralnik JM. Disability in older adults: evidence regarding significance, etiology, and risk. J Am Geriatr Soc. 1997;45:92–100.
Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146–56.
Espinoza S, Walston JD. Frailty in older adults: insights and interventions. Cleve Clin J Med. 2005;72:1105–12.
Morley KC, Cornish JL, Li KM, McGregor IS. Preexposure to MDMA (“Ecstasy”) delays acquisition but facilitates MDMA-induced reinstatement of amphetamine self-administration behavior in rats. Pharmacol Biochem Behav. 2004;79:331–42.
Kotler DP. Cachexia. Ann Intern Med. 2000;133:622–34.
Rosenbaum K, Wang J, Pierson Jr RN, Kotler DP. Time-dependent variation in weight and body composition in healthy adults. JPEN J Parenter Enteral Nutr. 2000;24:52–5.
Yeh SS, Schuster MW. Geriatric cachexia: the role of cytokines. Am J Clin Nutr. 1999; 70:183–97.
Morley JE, Baumgartner RN. Cytokine-related aging process. J Gerontol A Biol Sci Med Sci. 2004;59:M924–9.
Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med. 2000;51:245–70.
Cappola AR, Xue QL, Ferrucci L, Guralnik JM, Volpato S, Fried LP. Insulin-like growth factor I and interleukin-6 contribute synergistically to disability and mortality in older women. J Clin Endocrinol Metab. 2003;88:2019–25.
Sullivan DH, Morley JE, Johnson LE, et al. The GAIN (Geriatric Anorexia Nutrition) registry: the impact of appetite and weight on mortality in a long-term care population. J Nutr Health Aging. 2002;6:275–81.
Ritchie CS, Locher JL, Roth DL, McVie T, Sawyer P, Allman R. Unintentional weight loss predicts decline in activities of daily living function and life-space mobility over 4 years among community-dwelling older adults. J Gerontol A Biol Sci Med Sci. 2008;63:67–75.
Argiles JM, Busquets S, Felipe A, Lopez-Soriano FJ. Molecular mechanisms involved in muscle wasting in cancer and ageing: cachexia versus sarcopenia. Int J Biochem Cell Biol. 2005; 37:1084–104.
Conn MP, Bowers CY. A new receptor for growth hormone-release peptide. Science. 1996; 273:923.
Bowers CY, Chang JK, Fong TTW. A synthetic pentapeptide which specifically releases GH, in vitro. Proceedings of the 59th Meeting of The Endocrine Society. Chicago; 1977.
Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114:1537–45.
Chapman IM, Hartman ML, Pezzoli SS, Thorner MO. Enhancement of pulsatile growth hormone secretion by continuous infusion of a growth hormone-releasing peptide mimetic, L-692,429, in older adults—a clinical research center study. J Clin Endocrinol Metab. 1996;81:2874–80.
Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273:974–7.
Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656–60.
Kojima M, Hosoda H, Matsuo H, Kangawa K. Ghrelin: discovery of the natural endogenous ligand for the growth hormone secretagogue receptor. Trends Endocrinol Metab. 2001; 12:118–22.
Guerlavais V, Boeglin D, Mousseaux D, et al. New active series of growth hormone secretagogues. J Med Chem. 2003;46:1191–203.
Bednarek MA, Feighner SD, Pong SS, et al. Structure-function studies on the new growth hormone-releasing peptide, ghrelin: minimal sequence of ghrelin necessary for activation of growth hormone secretagogue receptor 1a. J Med Chem. 2000;43:4370–6.
Matsumoto M, Hosoda H, Kitajima Y, et al. Structure-activity relationship of ghrelin: pharmacological study of ghrelin peptides. Biochem Biophys Res Commun. 2001;287:142–6.
Tschoep M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature. 2000;407:908–13.
Tschoep M, Tataranni PA, Weyer C et al. Circulating human ghrelin and the regulation of energy balance. Proceedings of the 83rd Meeting of The Endocrine Society. Denver, CO; 2001:129.
Smith RG. Development of growth hormone secretagogues. Endocrinol Rev. 2005;26:346–60.
Torsello A, Luoni M, Schweiger F, et al. Novel hexarelin analogs stimulate feeding in the rat through a mechanism not involving growth hormone release. Eur J Pharmacol. 1998;360:123–9.
Gnanapavan S, Kola B, Bustin SA, et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab. 2002;87:2988–91.
van der Lely AJ, Tschop M, Heiman ML, Ghigo E. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocrinol Rev. 2004;25:426–57.
Sun Y, Ahmed S, Smith RG. Deletion of ghrelin impairs neither growth nor appetite. Mol Cell Biol. 2003;23:7973–81.
Zhao TJ, Liang G, Li RL, et al. Ghrelin O-acyltransferase (GOAT) is essential for growth hormone-mediated survival of calorie-restricted mice. Proc Natl Acad Sci USA. 2010;107: 7467–72.
Nass RM, Gaylinn BD, Rogol AD, Thorner MO. Ghrelin and growth hormone: story in reverse. Proc Natl Acad Sci U S A. 2010;107:8501–2.
Liu J, Prudom CE, Nass R, et al. Novel ghrelin assays provide evidence for independent regulation of ghrelin acylation and secretion in healthy young men. J Clin Endocrinol Metab. 2008; 93:1980–7.
Dixit VD, Schaffer EM, Pyle RS, et al. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest. 2004; 114:57–66.
Li WG, Gavrila D, Liu X, et al. Ghrelin inhibits proinflammatory responses and nuclear factor-kappaB activation in human endothelial cells. Circulation. 2004;109:2221–6.
Rigamonti AE, Pincelli AI, Corra B, et al. Plasma ghrelin concentrations in elderly subjects: comparison with anorexic and obese patients. J Endocrinol. 2002;175:R1–5.
Nass R, Liu J, Pezzoli SS, Oliveri MC, Gaylinn BD, Thorner MO. 24-h Mean acyl-ghrelin levels are decreased in older adults. 4th International Congress of the GRS and the IGF Society. Genoa, Italy; 2008:51.
Nagaya N, Itoh T, Murakami S, et al. Treatment of cachexia with ghrelin in patients with COPD. Chest. 2005;128:1187–93.
Nagaya N, Kojima M, Kangawa K. Ghrelin, a novel growth hormone-releasing peptide, in the treatment of cardiopulmonary-associated cachexia. Intern Med. 2006;45:127–34.
Vestergaard ET, Hansen TK, Gormsen LC, et al. Constant intravenous ghrelin infusion in healthy young men: clinical pharmacokinetics and metabolic effects. Am J Physiol Endocrinol Metab. 2007;292:E1829–36.
Murphy MG, Plunkett LM, Gertz BJ, et al. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. J Clin Endocrinol Metab. 1998;83:320–5.
Chapman IM, Bach MA, Van Cauter E, et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab. 1996;81:4249–57.
Svensson J, Lonn L, Jansson JO, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab. 1998;83:362–9.
Murphy MG, Weiss S, McClung M, et al. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab. 2001; 86:1116–25.
Bach MA, Rockwood K, Zetterberg C, et al. The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture. J Am Geriatr Soc. 2004;52:516–23.
Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008; 149: 601–11.
White HK, Petrie CD, Landschulz W, et al. Effects of an oral growth hormone secretagogue in older adults. J Clin Endocrinol Metab. 2009;94:1198–206.
Garcia JM, Polvino WJ. Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers. Oncologist. 2007;12:594–600.
Garcia J, Boccia RV, Graham C, Kumor K, Polvino W. A phase II randomized, placebo-controlled, double-blind study of the efficacy and safety of RC-1291 (RC) for the treatment of cancer cachexia [abstract]. J Clin Oncol. 2007;S25.
Piccoli F, Degen L, MacLean C, et al. Pharmacokinetics and pharmacodynamic effects of an oral ghrelin agonist in healthy subjects. J Clin Endocrinol Metab. 2007;92:1814–20.
MacLean CM, Casanova AT, Baselgia-Jeker L, et al. Effect of food on the pharmacokinetics and pharmacodynamics of an oral ghrelin agonist (ARD-07) in healthy subjects. J Clin Pharmacol. 2009;49:553–9.
Lasseter KC, Shaughnessy L, Cummings D, et al. Ghrelin agonist (TZP-101): safety, pharmacokinetics and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study. J Clin Pharmacol. 2008;48:193–202.
Zdravkovic M, Sogaard B, Ynddal L, et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of NN073, a novel orally active growth hormone secretagogue in healthy male volunteers. Growth Horm IGF Res. 2000;10:193–8.
Gertner J. SUN 11031 (synthetic human ghrelin) improves lean body mass and function in advanced COPD cachexia in a placebo controlled trial. 5th International Congress of the GRS and IGF Society. New York; 2010.
Roddam AW, Allen NE, Appleby P, et al. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med. 2008;149:461–71.
van Bunderen CC, van Nieuwpoort IC, van Schoor NM, Deeg DJ, Lips P, Drent ML. The association of serum insulin-like growth factor-I with mortality, cardiovascular disease, and cancer in the elderly: a population-based study. J Clin Endocrinol Metab. 2010;95:4616–24.
Holly J. Insulin-like growth factors (IGFs) and IGF binding proteins in PSA-detected prostate cancer: a population-based case control study. 5th International Congress of the GRS and IGF Society. New York; 2010.
Koo GC, Huang C, Camacho R, et al. Immune enhancing effect of a growth hormone secretagogue. J Immunol. 2001;166:4195–201.
Svensson J, Fowelin J, Landin K, Bengtsson BA, Johansson JO. Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults. J Clin Endocrinol Metab. 2002;87:2121–7.
Strasser F, Lutz TA, Maeder MT, et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. Br J Cancer. 2008;98:300–8.
Neary NM, Small CJ, Wren AM, et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004; 89:2832–6.
Broglio F, Gianotti L, Destefanis S, et al. The endocrine response to acute ghrelin administration is blunted in patients with anorexia nervosa, a ghrelin hypersecretory state. Clin Endocrinol. 2004;60:592–9.
Miljic D, Pekic S, Djurovic M, et al. Ghrelin has partial or no effect on appetite, growth hormone, prolactin, and cortisol release in patients with anorexia nervosa. J Clin Endocrinol Metab. 2006;91:1491–5.
Takala J, Ruokonen E, Webster NR, et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med. 1999;341:785–92.
Golden AG, Daiello LA, Silverman MA, Llorente M, Preston RA. University of Miami Division of Clinical Pharmacology Therapeutic Rounds: medications used to treat anorexia in the frail elderly. Am J Ther. 2003;10:292–8.
Lambert CP, Sullivan DH, Freeling SA, Lindquist DM, Evans WJ. Effects of testosterone replacement and/or resistance exercise on the composition of megestrol acetate stimulated weight gain in elderly men: a randomized controlled trial. J Clin Endocrinol Metab. 2002; 87:2100–6.
Evans WJ. Editorial: megestrol acetate use for weight gain should be carefully considered. J Clin Endocrinol Metab. 2007;92:420–1.
Wilson MM, Philpot C, Morley JE. Anorexia of aging in long term care: is dronabinol an effective appetite stimulant?—a pilot study. J Nutr Health Aging. 2007;11:195–8.
Bhasin S, Wu F. Making a diagnosis of androgen deficiency in adult men: what to do until all the facts are in? Nat Clin Pract Endocrinol Metab. 2006;2:529.
Sattler FR, Castaneda-Sceppa C, Binder EF, et al. Testosterone and growth hormone improve body composition and muscle performance in older men. J Clin Endocrinol Metab. 2009;94: 1991–2001.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media New York
About this chapter
Cite this chapter
Nass, R., Thorner, M.O. (2012). Ghrelin Receptor Agonists in Cachexia of Human Aging. In: Smith, R., Thorner, M. (eds) Ghrelin in Health and Disease. Contemporary Endocrinology, vol 10. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-903-7_11
Download citation
DOI: https://doi.org/10.1007/978-1-61779-903-7_11
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61779-902-0
Online ISBN: 978-1-61779-903-7
eBook Packages: MedicineMedicine (R0)